ALCAM and prostate carcinoma: Actually, PSAlo and CD166+ cells were also increased with tumor grade in prostate cancer patients (43 patients for PSAlo and 112 patients for CD166+) and demonstrated increased sphere formation [38, 39], indicating a possible self-renewal capacity.